Shorts

0:33
Why Use Frontline Bispecifics in Myeloma
a year ago
by
Marc Raab, MD

0:33
Why "One Size" Policies Fail Rural Communities
a year ago
by
Enrique Soto Pérez de Celis, MD, MSc

0:35
Shifting Health Care Culture Requires Everyone Learning Together
a year ago
by
Cheyenne Corbett

0:35
Why Cancer Care Needs a "Both/And" Approach
a year ago
by
Cheyenne Corbett

0:32
Ego vs the Patient: The Hardest Medical Decision
a year ago
by
Cheyenne Corbett

0:26
Why Oncology is a "Black Box" for Most Primary Care Providers
a year ago
by
Cheyenne Corbett

0:37
The Silent Crisis in Rural Health Care
a year ago
by
Enrique Soto Pérez de Celis, MD, MSc

0:38
Can Quality Cancer Care Reach Rural America?
a year ago
by
Enrique Soto Pérez de Celis, MD, MSc

0:41
The Biggest Challenges Facing Rural Cancer Care
a year ago
by
Enrique Soto Pérez de Celis, MD, MSc

1:01
The Power of Perseverance: Finding Strength in Shared Journeys
a year ago
by
Jered Haddad

0:38
Empowering Conversations: A Guide for Supporting New Diagnoses
a year ago
by
Jered Haddad

0:48
The Best Advice From an Oncologist to a Patient
a year ago
by
Michael Cole

0:41
Unlocking New Possibilities in Bladder Cancer Treatment
a year ago
by
Andrea Necchi, MD

1:23
Dr Patel: Considerations for Adjuvant Cemiplimab in CSCC
a year ago
by
Vishal A. Patel, MD

1:10
Trial Opens Up More Avenues for Treatment in Patients with Bladder Cancer
a year ago
by
Christof Vulsteke, MD, PhD

0:41
A 13-Year-Old Drug’s Persisting Power in Prostate Cancer
a year ago
by
Stephen J. Freedland, MD

1:16
Clinical Trial Achieves 60% Reduction in the Risk of Tumor Recurrence
a year ago
by
Christof Vulsteke, MD, PhD

1:22
Pembrolizumab and Enfortumab Vedotin Demonstrate Potential in Bladder Cancer Treatment
a year ago
by
Christof Vulsteke, MD, PhD

0:36
Delaying Progression in Nonmetastatic Prostate Cancer: Insights from EMBARK
a year ago
by
Stephen J. Freedland, MD

1:11
Perioperative Pembrolizumab Doubles Survival in Metastatic Bladder Cancer
a year ago
by
Christof Vulsteke, MD, PhD

0:29
The Challenge of Treating High-Risk nmCSPC
a year ago
by
Stephen J. Freedland, MD

0:35
Frontline Strategy: Why You Must Use IO Upfront in Endometrial Cancer
a year ago
by
Bradley J. Monk, MD

0:30
Adverse Events to Watch for With Ribociclib
a year ago
by
Sara A. Hurvitz, MD

0:45
Dr Mayer Discusses PFS Data From evERA at ESMO 2025
a year ago
by
Erika Mayer, MD, MPH

0:19
How a New Drug is Changing Breast Cancer Treatment Forever
a year ago
by
Joyce A. O’Shaughnessy, MD

0:21
1 in 3 Breast Cancer Patients at High Risk
a year ago
by
Joyce A. O’Shaughnessy, MD

0:37
Why Understanding Tumor Biology is Key to Better Breast Cancer Care
a year ago
by
Sarah Premji, MD

0:37
FDA Requires 5 Years of Follow Up—Is It Too Much?
a year ago
by
Harpreet Singh, MD

0:20
How Breast Cancer Treatment Became More Personalized & Effective
a year ago
by
Sarah Premji, MD

0:17
Reviewing the FDA Draft Guidance on Radiopharmaceuticals
a year ago
by
Harpreet Singh, MD
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Approves Neladalkib for Previously Treated Advanced ALK-Positive NSCLC
2
Galinpepimut-S Improves Overall Survival in Phase 3 REGAL Trial in AML
3
FDA Fast Tracks Elticertinib for Previously Treated EGFR Exon 20 NSCLC
4
FDA Approves Giredestrant Plus Everolimus in ESR1-Mutated Breast Cancer
5
